lifesciencesdeals.blogspot.com
Life Sciences Deals: We Have Moved
http://lifesciencesdeals.blogspot.com/2009/12/we-have-moved.html
Thursday, December 24, 2009. Http:/ biopharmadeals.wordpress.com/. Subscribe to: Post Comments (Atom). Random thoughts about financing biotechnology, pharmaceutical, and medical device companies. Includes topics regarding venture capital funding, mergers and acquisitions, and licensing deals. PhD, MBA currently working in business development at a biotechnology company. Previous jobs include venture capital, equity research, and medical marketing. View my complete profile. A Notice to Readers.
pharmalyst.blogspot.com
Pharmalyst (Pharmalyst@gmail.com): Pharmalyst RIP
http://pharmalyst.blogspot.com/2007/11/pharmalyst-rip.html
Saturday, November 17, 2007. Pharmalyst just came off the campus recruiting season and this explains the lack of any posts prior to this one in November. Thank you all again (and for those in the US - wish you a happy thanksgiving! Pharmalyst definitely has many things to be thankful for). Cheers. I wish you well Pharmalyst, but I'm afraid you'll find out soon enough that you've just entered the belly of the beast. November 19, 2007 at 12:57 PM. November 25, 2007 at 9:12 AM. November 25, 2007 at 7:49 PM.
realmofquality.blogspot.com
Realm of Quality -: MHRA Publishes OOS FAQs
http://realmofquality.blogspot.com/2012/05/mhra-publishes-oos-faqs.html
Realm of Quality -. Viewpoint on - GMPs, - Pharmaceutical Manufacturing Systems Management, -Regulatory Compliance and related Corporate Strategies. Thursday, May 24, 2012. MHRA Publishes OOS FAQs. FDAs guidance on Out-of-specifications (OOS) is well known. Now Guidance from the MHRA on how to handle out-of-specification results during laboratory analysis is - on the contrary - pretty unknown although an own webpage on the MHRA website is dedicated to the OOS topic. To read and download the guidance.
realmofquality.blogspot.com
Realm of Quality -: CDSCO Website in its improved version with inclusion of Industry Guidance Documents
http://realmofquality.blogspot.com/2010/08/cdsco-website-in-its-improved-version.html
Realm of Quality -. Viewpoint on - GMPs, - Pharmaceutical Manufacturing Systems Management, -Regulatory Compliance and related Corporate Strategies. Saturday, August 28, 2010. CDSCO Website in its improved version with inclusion of Industry Guidance Documents. CDSCO website in new avatar. Since my last visit to the website, may be at a gap of a year, I realise, CDSCO has included various multidisciplinary topics. Navigation is made easy and search relatively better. To reach the website, click here.
hematologymarketinsights.blogspot.com
Hematology Competitive Insights: Second-line treatment in CML
http://hematologymarketinsights.blogspot.com/2008/07/second-line-treatment-in-cml.html
Tuesday, July 29, 2008. Second-line treatment in CML. MD Anderson Cancer Center recently published a new article in Blood. Looking at second-line treatment with tyrosine kinase therapies with nilotinib. Failure. This is a crucial question - how long should patients receive their new therapy before considering alternative treatments? Thanks for this useful post. Here is some additional information about the genetics of this condition that was written by our Genetic Counselor and other genetic professi...
hematologymarketinsights.blogspot.com
Hematology Competitive Insights: May 2008
http://hematologymarketinsights.blogspot.com/2008_05_01_archive.html
Monday, May 12, 2008. Knocking out cancer cells in Leukemia. Cancer initiating cells (CICs) or leukemia initiating cells (LICs) are stealth populations impervious to conventional chemotherapy and resistant to targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that are the cause of the disease’s re-emergence. Researchers at the Beth Israel Deaconess Medical Center. Their findings, which appear in Nature. The concept is a very simple one; 90% of exis...
science-line.blogspot.com
Science Line: QUB's Misleading PR
http://science-line.blogspot.com/2011/06/qubs-misleading-pr.html
Sounding off on science. Wednesday, June 22, 2011. Top marks to the publicity department at Queen's University Belfast for getting broad TV and print coverage. For their role in the development of a new cystic fibrosis drug, called ivacaftor or VX-770. It's the first disease-modifying therapy in cystic fibrosis, so it's an important development,even if only a small percentage of CF patients (those with the G551D or 'Celtic' mutation) will benefit. But on reading the press release. Im a freelance science ...
rnaitherapeutics.blogspot.com
RNAi Therapeutics: December 2014
http://rnaitherapeutics.blogspot.com/2014_12_01_archive.html
Wednesday, December 31, 2014. Tekmira Enters 2015 a Different Company. Today is the last official day. After generation 1, 2, 3, and now even 4 SNALP LNP, and 10, 100, 1000x fold improvements in the potency and therapeutic window, the time has come to stop telling us that ‘ next time will be better. However, with the recent initiation of phase I studies of generations 3 and 4 formulation of TKM-HBV. And the departure of Dr MacLachlan, the company seems comfortable with taking their last two shots at prov...
rnaitherapeutics.blogspot.com
RNAi Therapeutics: Alnylam Slams Dicerna with Trade Secret Complaint
http://rnaitherapeutics.blogspot.com/2015/06/alnylam-slams-dicerna-with-trade-secret.html
Wednesday, June 10, 2015. Alnylam Slams Dicerna with Trade Secret Complaint. How times have changed. Four years ago, Alnylam found itself. On the receiving end of a trade secret lawsuit regarding the delivery technology du jour, SNALP LNP then, in which it ended up paying. Near-bankrupt Tekmira $70M to settle the allegations. As I opined back then. At that time, all Alnylam's CEO had to say on the topic of honoring trade secrets: ' you pay for it, you own it. Tonight, Alnylam claims to be the victim.
SOCIAL ENGAGEMENT